CAR T-cell therapy for lung cancer: current landscape and emerging strategies
Experimental Hematology · 2026-11 · 105983
DOI: 10.1016/j.exphem.2026.105983 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Experimental Hematology, 2026-11. Verfasst von Koki Ito und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Agency Fusion Oriented REsearch for disruptive Science and Technology, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.
- Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan. Electronic address: ykagoya@keio.jp.
Förderung
- Japan Science and Technology Agency Fusion Oriented REsearch for disruptive Science and Technology
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Ito, K., & Kagoya, Y. (2026). CAR T-cell therapy for lung cancer: current landscape and emerging strategies. Experimental Hematology, 105983. https://doi.org/10.1016/j.exphem.2026.105983
Vancouver
Ito K, Kagoya Y. CAR T-cell therapy for lung cancer: current landscape and emerging strategies. Experimental Hematology. 2026:105983. doi:10.1016/j.exphem.2026.105983
BibTeX
@article{Ito2026,
author = {Ito, Koki and Kagoya, Yuki},
title = {CAR T-cell therapy for lung cancer: current landscape and emerging strategies},
journal = {Experimental Hematology},
year = {2026},
pages = {105983},
doi = {10.1016/j.exphem.2026.105983}
}
EUVIMED